Shares shifted as Rezolute (RZLT) jumped +10.84% to $4.50 on September 10, defying a down market after disclosing that the FDA's review of its failed Phase 3 trial data remains actively ongoing. For a company whose lead drug missed the statistical bar regulators typically demand, the fact that the FDA is still engaging — rather than shutting the door — is the only thread keeping investor hopes alive.
The Trial Failed on Paper, but the FDA Hasn't Said No
The pivotal trial showed reductions from baseline in hypoglycemia events but did not meet its primary or key secondary endpoints versus placebo. The core problem: there was an approximate 45% reduction in hypoglycemia events at the top dose, which was not statistically significant compared to the placebo group, which experienced a 40% improvement. That razor-thin gap is brutal in a rigorous trial design. Yet at FDA's request, Rezolute submitted source and analysis datasets, including numerous pre-specified, post-hoc, and sensitivity analyses focused on continuous glucose monitoring outcomes. The agency asking for more data — rather than issuing a rejection — is what the market is pricing in today.
The Company Is Leaning on Backup Metrics the FDA Hasn't Endorsed
The company believes these data show consistent glycemic improvements, including ≥50% reductions in average daily percent time in hypoglycemia and average weekly hypoglycemia events.
Although statistical significance for the secondary endpoint was not achieved at the end-of-treatment window, larger and often nominally significant glycemic improvements were consistently observed throughout the maintenance dosing phase. Rezolute is essentially asking the FDA to credit alternative measurements the trial wasn't designed to prove — a long-odds strategy.
Cash Runway Is Tight Against an Open-Ended Regulatory Timeline
Cash, cash equivalents, and investments totaled $120.3 million as of March 31, 2026, providing runway for at least 12 months.
The company has stated additional financing will be needed for longer-term needs, and a workforce reduction of roughly 29 employees in December 2025 underscores management's focus on extending runway. With uncertainty regarding the FDA's timeline for feedback and a market cap near $440 million, investors are paying roughly 3.7x cash for a binary regulatory outcome with no deadline.
A Second Trial Offers a Hedge — but Not a Rescue
Rezolute continues to recruit patients in its Phase 3 upLIFT study for tumor-related hyperinsulinism and remains on track to report topline results before the end of 2026. That trial targets a different form of the disease where only one therapy — diazoxide — is currently FDA-approved for managing congenital hyperinsulinism. A win there could salvage the pipeline, but it cannot erase the sunRIZE miss. Until the FDA delivers a verdict, RZLT remains a pure speculation on regulatory flexibility in rare disease — and today's rally reflects hope, not evidence.